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ABSTRACT 
Fifteen new multifunctional conjugates were designed and synthesized by chemically linking the 
steroidal framework of natural occurring γ-oryzanol and γ-oryzanol-derived phytosterols to a wide 
range of bioactive natural compounds (fatty acids, phenolic acids, amino acids, lipoic acid, retinoic 
acid, curcumin and resveratrol). Starting from γ-oryzanol, which is the main component of rice bran 
oil, this study was aimed at assessing if the conjugation strategy might enhance some γ-oryzanol 
bioactivities. The antioxidant activity was evaluated through three different mechanisms, namely the 
DPPH scavenging activity, the metal chelating activity and the β-carotene bleaching inhibition. 
Measurement of the in vitro cell growth inhibitory effects on three different human cancer cellular 
lines was also carried out and the potential hypocholesterolemic effect was studied. Compounds 10 
and 15 displayed an improved antioxidant activity, with respect to that of γ-oryzanol. Compounds 2, 
6 and 12 exerted an antiproliferative activity in the low µmolar range against HeLa and DAOY cells 
(GI50<10 µM). As for the claimed hypocholesterolemic effect of γ-oryzanol, none of the synthesized 
compounds could inhibit the 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCoAR), a key 
enzyme in cholesterol biosynthesis. 
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Phytosterols are a large group of compounds that are found exclusively in plants, being essential 
components of plant membranes. In addition to their primary function of controlling membrane-
associated metabolic processes, phytosterols are also precursors of plant growth factors, thus playing 
a role in cellular differentiation and proliferation.1 Phytosterols are triterpenes structurally related to 
cholesterol which differ from it in the side chain. Due to this chemical similarity, phytosterols 
effectively reduce the levels of total cholesterol and low density cholesterol in blood, by inhibiting 
its absorption from the intestine in humans.2,3 Considerable emerging evidence supports also the 
antiproliferative effect of phytosterols through multiple mechanisms of action, ranging from 
inhibition of carcinogen production, cancer-cell growth and angiogenesis, to the promotion of 
cancerous cells apoptosis.4 Phytosterols action seems to be related to an increased activity of 
antioxidant enzymes and thereby oxidative stress reduction.5 Further applications for phytosterols in 
the fields of pharmaceuticals, health products, and cosmetics are being developed, although the poor 
solubility of phytosterols in water and fat is a critical issue. 
Besides free phytosterols, plant materials and vegetable oils contain phytosterol esters, that are 
derived from esterification of the C3 hydroxyl group of phytosterols with fatty acids. Phytosterol 
esters possess the same physiological activity as phytosterols and, at the same time, the advantage of 
a better lipid solubility as well as an easy hydrolysis in the human body. Steryl ferulates are the esters 
of phytosterols and ferulic acid. They are present in the bran of some grains such as rice (Oryza sativa 
L.), wheat (Triticum aestivum L.) and corn (Zea mays L.).6,7 The sterol component from rice bran oil 
(RBO), which is called γ-oryzanol (ORY), is mainly composed of cycloartenyl ferulate, 24-
methylenecycloartanyl ferulate and campesteryl ferulate, generally accounting for approximately 
80% of ORY in RBO.8,9 
To date, many papers have reported the benefit of RBO and ORY in treating dyslipidemia, by 
lowering cholesterol.10,11,12 With regard to the antioxidant effect, as for all steryl ferulates, it is likely 
the result of the radical scavenging activity of the phenolic component of ORY.13 It has been reported 
that ORY can inhibit the oxidation of linoleic acid to a higher extent than vitamin E and that it can 
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also prevent peroxide formation by inhibiting reactive oxygen species (ROS).14,15 Many studies have 
demonstrated that the main biologically active components in RBO are responsible for inducing 
apoptosis in colon cancer, breast and pancreatic cancer cells.16,17 ORY seems also to be of interest for 
adjuvant chemotherapy, affecting prostate cancer cells through the down regulation of some 
antioxidant genes.18 
An up to date approach to the design of new therapeutic agents is based on the conjugation of 
compounds whose biological activity is known.19,20,21 This may lead to new biologically relevant 
properties or to synergistic effects either on single or dual targets. Multifunctional conjugates may 
also bring their therapeutic effects at lower concentrations compared to the single molecules alone. 
Phytosterols and steryl ferulates exhibited biological activity only at a high concentration and, 
therefore, they cannot be considered as the main components of medicinal preparations. 
We envisioned ORY being an attractive candidate for this conjugation/hybrid strategy, based on 
both its chemical and biological properties. In continuation of our previous work, aimed at developing 
diversified, bioactive steroidal compounds,22 we herein report the synthesis of phytosterols and ORY 
conjugates, in which various relevant, naturally occurring compounds are chemically linked to the 
steroidal framework. For preparing new hybrid molecules, fatty acids, phenolic acids, amino acids, 
lipoic acid, retinoic acid, curcumin and resveratrol were selected as ligands, with the aim to enhance 
some of the relevant bioactivities of phytosterols and ORY. All conjugates were screened for their 
antioxidant, antiproliferative and anticholesterol activity. 
 
RESULTS AND DISCUSSION 
To the aim of the present study, commercially available ORY was employed. It consists of a mixture 
of cycloartenyl ferulate (a), 24-methylene-cycloartanyl ferulate (b), campesteryl ferulate (c) and 
sitosteryl ferulate (d) (a/b/c+d:1/3/1, as confirmed by 1H NMR). The molecular structures of the main 
phytosterols, present in ORY as ferulate esters, are shown in Figure 1. 
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Figure 1. Chemical structure of ORY 
 
We identified the phenolic group of ORY and the C3-hydroxy group of phytosterols as ideal sites 
for chemical variations through covalent linkages with naturally occurring bioactive compounds 
(Figure 2). 
 
Figure 2. General chemical structures of synthesized oryzanol- and phytosterol-conjugates (ORY-
C and PS-C, respectively) 
 
The choice of bioactive natural compounds for conjugation was addressed by their inherent 
biological relevance. Among important good health associated metabolic agents, we selected a 
polyunsaturated fatty acid such as linoleic acid and the vitamine A metabolite retinoic acid. Moreover, 
lipoic acid and two phenolic acids (gallic acid and caffeic acid) were chosen as antioxidant 
compounds. The conjugation of ORY with these bioactive components was carried through an ester 
linkage, as reported in Scheme 1.  
 
Scheme 1. Synthesis of ORY-Conjugates (ORY-C) 1-5 
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ORY-conjugates (ORY-C) 1-5 were obtained in good to excellent yields (67-98%) and fully 
characterized by 1H NMR, 13C NMR, 2D NMR techniques and ESI mass spectrometry. The 1H and 
13C NMR spectra of 1-5 are given in the Supporting Information and are in good agreement with the 
expected structures. In the experimental section, 1H NMR selected spectroscopic data are provided to 
establish the formation of the product and to assess the actual ratio of components, for what concerns 
the phytosterol moiety. In all products, the original a/b/cd:1:3:1 ratio is substantially retained. Full 
assignment of 13C NMR signals is also provided for the dominant cycloartenol-based a,b component. 
In order to modulate the potential dual action of the target compounds, by varying the distance 
between the phytosterol pharmacophore and the linked bioactive natural organic acid, phytosterol-
conjugates were also synthesized, lacking the ferulic acid linker component. 
Basic hydrolysis of ORY afforded phytosterols in high yield, with the complete maintenance of the 
a/b/cd:1:3:1 ratio among phytosterol components, as in native ORY. Phytosterol-conjugates 6-10 
were obtained in good yields (67-94%, Scheme 2) and fully characterized, as described above for 1-
5. 
Finally, starting from phytosterols, the small library was completed with the synthesis of the 
cysteine derivative 12 (synthesized through Bu3P-mediated reduction of cystine-based intermediate 
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11, Scheme 3a) and of hybrid compounds 13, 14 and 15, containing resveratrol, vanillin or curcumin 
moieties, respectively (Scheme 3b,c). 
 
Scheme 2. Synthesis of Phytosterol-Conjugates (PS-C) 6-10 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. Synthesis of Phytosterol-Conjugates (PS-C) a) 11-12 b) 13 (as 1:1.5 inseparable 
mixture of 13’ and 13”) c) 14-15 
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For the preparation of 13-15, a succinic acid-based linker was selected. Phytosterol was reacted 
with succinic anhydride to give the phytosteryl hemisuccinate intermediate (PS-HS) in high yield. 
Condensation of PS-HS with trans-resveratrol afforded 13 as a 1:1.5 inseparable mixture of 13’ and 
13” isomers.  
From PS-HS and vanillin, the conjugate 14 could be easily obtained. Finally, condensation of 14 
with naturally derived hispolon methyl ether afforded the curcumin conjugate 15 in 44% yield. 
The knowledge of the complex system of natural enzymatic and non-enzymatic antioxidant 
defenses of the human body led to develop a large array of methods for antioxidant activity23 
evaluation. Being aware that such an activity should not be concluded from a single antioxidant test 
model, we performed three different in vitro assays, aimed at evaluating the potential of newly 
synthesized compounds to contrast the harmful effects of free radicals and other oxidants, through 
various mechanisms. 
The potential free radical scavenging capacity of conjugates 1-15 was evaluated by using the DPPH 
method, thus UV monitoring the change in optical density of DPPH radicals. The results are given as 
percentage of radical inhibition, using butylated hydroxyanisole (BHA) as the standard positive 
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control (Table 1, first column). ORY proved to be effective in DPPH inhibition (58%), thus 
confirming the recently reported data24 and supporting the interest in ORY for adjuvant chemotherapy 
in some types of cancer, where an imbalance of the oxidant-antioxidant system is recognized as an 
important feature.18 Among conjugates, it clearly emerged that many of them were even more 
effective than ORY, with in particular compounds 10 and 15 showing inhibition percentages similar 
to those of the positive control BHA. 
As excess free irons have been implicated in the induction and formation of free radicals in 
biological systems, we tested compounds 1-15 in a metal chelating assay. We used the Mohr’s 
salt/ferrozine system and measured the absorbance at 545 nm, thus evaluating the decrease of the red 
colour of the ferrozine-Fe2+ complexes (Table 1, second column). The results, expressed as 
percentage of chelated ferrous ions and compared with quercetine (used as the reference standard), 
showed that ORY was inactive. Compound 10 demonstrated a surprisingly high activity, while 
compound 15 showed to be as active as the reference. 
The antioxidant activity was also evaluated by using the β-carotene-linoleic acid method. This 
protocol is mainly based on the principle that linoleic acid, which is an unsaturated fatty acid, gets 
oxidized by reactive oxygen species produced by oxygenated water. The products formed initiate the 
β-carotene oxidation, which leads to discoloration. Antioxidants decrease the extent of discoloration, 
which is measured at 450 nm, thus determining the bleaching inhibition percentage (Table 1, third 
column). Both ORY and all synthesized compounds were less active than the reference BHA. 
However, almost all tested compounds inhibited linoleic acid oxidation, although to a different extent.  
From the above data, conjugation of ORY and phytosterols with natural compounds resulted in an 
increased antioxidant activity, in particular for the inhibition of the DPPH radical and for the Fe2+ 
chelating activity. Some newly synthesized compounds performed better than ORY, equaling or even 
surpassing the activity of the positive control at the same concentration. The most active compounds 
are 10 and 15, bearing a caffeic acid and a curcumin unit, respectively. Even if it is not possible to 
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draw conclusive information about structure-activity relationships, phenolic hydroxyl groups and 
aromatic-double bond conjugation can be recognized to play a role in antioxidant activity. 
The antiproliferative effects of ORY (used as the reference compound) and conjugates 1-15 against 
a panel of three human cancer cell lines are summarized in Table 1 (from fourth to sixth column). 
ORY was practically ineffective in HeLa and MDA-MB-468 cells (GI50>100 µM), whereas it was 
moderately active in medulloblastoma cells DAOY. Three out of the synthesized compounds 2, 6 and 
12 possessed the highest overall potency, with GI50 values ranging from 1.4 to 8.3 µM against HeLa 
and DAOY cell lines. 
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Table 1. Biological Evaluation of Conjugates 1-15 
 
aCompound (or positive control) concentration in the native solution: 0.18 μmol/mL (see Experimental Section for 
details). bGI50= compound concentration required to inhibit tumor cell proliferation by 50%. Data are expressed as the 
mean ± SE from the dose-response curves of at least three independent experiments. 
 
As for the hypocholesterolemic activity, although the effect of ORY has been widely demonstrated 
in various animal and human studies,25,26,27 the mechanisms responsible for this activity remain 
unclear.28 Recently, it has been reported29 that ORY can inhibit hepatic 3-hydroxy-3-methylglutaryl-
coenzyme A reductase (HMGCoAR) in a dose-dependent manner. HMGCoAR is the key enzyme of 
the mevalonate synthetic pathway that produces cholesterol. Inhibition of HMGCoAR reduces 
cholesterol biosynthesis in the liver. Statins are HMGCoAR inhibitors used as first-line drugs in the 
treatment of hypercholesterolemia.30  
Compounds 1-15 and ORY were evaluated as potential inhibitors of HMGCoAR through an in vitro 
assay by using the purified catalytic domain of this enzyme (see Experimental Section for details). 
The activity assay is based on the spectrophotometric measurement of the rate of oxidation of the 
compound 
inhibition 
of DPPH 
radical [%]a 
Fe2+ 
chelated 
[%]a 
β-
carotene 
bleaching 
inhibitio
n [%]a 
GI50 (µM) b 
      HeLa          MDA-MB-468        DAOY 
positive 
control 
95  
(BHA) 
22 
(quercetine) 
97  
(BHA) 
0.093±0.005 
(doxorubicin) 
0.046±0.009 
(doxorubicin) 
0.016±0.008 
(doxorubicin) 
ORY  58 0 54 >100 >100 >10 
1 9 0 11 >10 >10 >10 
2 13 0 27 8.3±6.3 >10 6.4±4.4 
3 0 0 36 >10 >10 8.3±4.4 
4 89 10 53 >100 >100 >10 
5 81 0 40 >100 >10 >10 
6 0 0 20 2.9±0.6 >10 6.0±3.8 
7 0 0 18 >10 >100 >10 
8 2 0 0 >100 >100 >100 
9 89 6 44 >100 >100 >100 
10 91 72 51 >100 >100 >100 
11 0 0 5 >100 >10 >10 
12 76 0 24 >10 >10 1.4±0.5 
13 41 0 17 >100 >10 >100 
14 0 0 29 >10 >10 8.7±2.4 
15 93 23 46 >10 >10 >10 
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cofactor (NADPH) at 340 nm. At the highest concentrations assayed, dictated by the poor water 
solubility of the tested compounds, no enzyme inhibition was detected (a decrease of NADPH 
absorbance was observed, thus indicating that the enzyme was active; data not shown). It is worth 
mentioning, however, that the concentration of the tested compounds was at least 20-fold higher than 
the concentration of the reference inhibitor (pravastatin). We hypothesized that the inconsistency 
between our data and the previous investigation29 might be attributed to multiple concurrent factors. 
It can be postulated that ORY may react through a different mechanism that does not involve the 
catalytic site targeted by statins.31 This evidence suggests that the anticholesterol activity exerted by 
ORY may depend on other mechanisms that do not involve necessarily HMGCoAR. 
 
EXPERIMENTAL SECTION 
General Experimental Procedures. γ-Oryzanol was purchased from TCI Chemicals. Commercial 
reagents were purchased from Sigma-Aldrich Chemical Co. and used without further purification. 
All solvents were of reagent grade or HPLC grade. All reactions were carried out under a nitrogen 
atmosphere unless otherwise noted. All reactions were monitored by thin-layer chromatography 
(TLC) on pre-coated silica gel 60 F254; spots were visualized with UV light or by treatment with a 
1% aqueous KMnO4 solution. Products were purified by flash chromatography on silica gel 60 
(230−400 mesh). 1H NMR spectra were recorded at 400 MHz, 13C NMR spectra were recorded at 
101 or 75 MHz (Bruker spectrometers). Chemical shifts are reported in parts per million relative to 
the residual solvent. 13C NMR spectra have been recorded using the APT pulse sequence. 
Multiplicities in 1H NMR are reported as follows: s = singlet, d = doublet, t = triplet, m = multiplet, 
br s = broad singlet. High resolution mass spectra were obtained in the ESI positive mode ((+)-
HRESIMS), from a Waters Micromass Q-Tof micro Mass spectrometer.  
All ORY conjugates (ORY-C) and PS conjugates (PS-C), obtained starting from commercial ORY, 
are described as a mixture of cycloartenyl (a), 24-methylene-cycloartanyl (b), campesteryl (c) and 
sitosteryl (d) derivatives, in a/b/c+d:1/3/1 relative ratio, as determined by NMR analysis. In 1H NMR 
13 
 
spectra, key 1H signals are unambiguously assigned for all a, b, c and d components, in order to 
confirm both the chemical structure and the components ratio. For reasons of brevity and clarity, in 
13C NMR spectra, signals are fully assigned exclusively for predominant (≥ 80%) a and b 
components. Reported, but not assigned, 13C NMR signals are to be ascribed to minor c and d 
components. In mass spectra, the exact mass assignment is reported exclusively for predominant a 
and b components. 
Synthesis of ORY-C 1-5 
General Procedure A (GP-A) for Esterification of ORY. To a stirred solution of ORY (0.2 mmol) 
and the appropriate carboxylic acid (0.24 mmol) in anhydrous dichloromethane (2.5 mL), under a 
nitrogen atmosphere at 0 °C, N,N'-dimethylaminopyridine (3 mg, 0.024 mmol) and EDC (38 mg, 0.24 
mmol) were added. The resulting mixture was stirred at room temperature for 8-24 hrs, until the 
conversion was found to be complete by TLC analysis. The resulting solution was diluted with EtOAc 
(20 mL) and washed with 5% aq. H3PO4 (3x10 mL), saturated aq. NaHCO3 (3x10 mL) and brine 
(3x10 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under 
reduced pressure to dryness. The resulting crude product was purified, if necessary, by flash column 
chromatography (FC) on silica gel, as described below.  
Compound 1. Prepared according to GP-A using linoleic acid; FC (n-hexane-EtOAc, 9:1); 67% 
yield; colourless oil; 1H NMR (400 MHz, CDCl3): δ 7.65 (1H, d, J = 15.7 Hz), 7.18-7.11 (2H, m), 
7.06 (1H, d, J = 7.9 Hz), 6.42 (0.8H, d, J = 15.7 Hz), 6.39 (0.2H, d, J = 15.7 Hz), 5.44-4.26 (4.2H, 
m), 5.13 (0.2H, t, br, J = 7.2 Hz, H-24a), 4.79 (0.1H, m, H-3d), 4.77-4.72 (1.5H, m, H-3a,b,c and H-
241b), 4.70 (0.6H, s, br, H-241b), 3.89 (2.4H, s), 3.87 (0.6H, s), 2.80 (2H, m), 2.61 (2H, t, J = 7.3 Hz),  
2.45-2.41 (0.4H, m), 2.27 (0.6H, sept, J = 6.8 Hz), 1.07 (1.8H, d, J = 6.8 Hz),  1.05 (1.8H, d, J = 6.8 
Hz), 0.92 (3H, t, J = 6.8 Hz), 0.71 (0.6H, s), 0.63 (0.8H, d, J = 4.1 Hz, H-19a,b endo), 0.39 (0.8H, d, 
J = 4.1 Hz, H-19a,b exo); 13C NMR (75 MHz, CDCl3) δ 171.7, 168.8 (1'), 156.9 (24b), 151.4 (7' and 
8'), 143.6 (3'), 133.4 (4'), 130.9 (25a), 130.2, 130.0, 128.1, 127.9, 125.3 (24a), 123.2 (5'), 121.3 (6'), 
119.0 (2'), 111.2 (9'), 106.0 (241b), 80.9 (3), 55.9 (10'), 52.3 (17), 48.8 (14), 47.9 (8), 47.2 (5), 45.3 
14 
 
(13), 39.7 (4), 36.3 (22a), 36.1 (20b), 35.9 (20a), 35.5 (12), 35.0 (22b), 34.1, 33.8 (25b), 32.9 (15), 
31.7 (1), 31.5 (23b), 31.3, 29.8 (19), 29.0, 28,1 (7), 27.2 (3C), 26.9 (2), 26.5 (16), 26.0 (10), 25.8 
(11), 25.7 (4C), 25.6 (26a), 25.5 (28), 25.0 (23a), 24.7, 22.6, 22.0 (27b), 21.9 (26b), 21.0 (6), 20.2 
(9), 19.3 (28), 18.3 (21), 18.0 (18), 17.6 (27a), 15.4 (29), 14.1; (+)-HRESIMS m/z 887.6531 [M+Na]+ 
(calcd for C58H88NaO5, 1a, 887.6524); m/z 901.6688 [M+Na]
+ (calcd for C59H90NaO5, 1b, 901.6680). 
Compound 2. Prepared according to GP-A using retinoic acid; 97% yield; colourless oil; 1H NMR 
(400 MHz, CDCl3): δ 7.66 (d, J = 15.9 Hz, 1H), 7.20-7.05 (4H, m), 6.42 (1H, d, J = 15.9 Hz), 6.40 
(1H, d, J = 15.4 Hz), 6.33 (1H, d, br, J = 16.1 Hz), 6.21 (1H, d, J = 11.5 Hz), 6.19 (1H, d, J = 16.1 
Hz), 6.07 (1H, s, br), 5.43 (0.2H, d, br, J = 4.2 Hz, H-6c,d), 5.13 (0.2H, t, br, J = 6.9 Hz,  H-24a), 
4.79 (0.1H, m, H-3d), 4.77-4.71 (1.5H, m, H-3a,b,c and H-241b), 4.69 (0.6H, s, br, H-241b), 3.90 
(2.4H, s), 3.88 (0.6H, s), 2.43 (3H, s, br), 2.05 (3H, s), 1.75 (3H, s), 1.08-1.03 (12H, m), 0.71 (0.6H, 
s), 0.63 (0.8H, d, J = 4.1 Hz, H-19a,b endo), 0.40 (0.8H, d, J = 4.1 Hz, H-19a,b exo); 13C NMR (101 
MHz, CDCl3) δ 166.8 (1'), 164.7, 156.9 (24b), 155.9, 151.7 (7'), 143.8 (3'), 141.5 (8'), 140.5, 137.7, 
137.2, 134.8, 133.2 (4'), 132.1, 130.9 (25a), 130.3, 129.4, 129.2, 125.3 (24a), 123.6 (5'), 121.3 (6'), 
118.9 (2'), 116.6, 111.2 (9'), 106.0 (241b), 80.9 (3), 56.0 (10'), 52.3 (17), 48.9 (14), 47.9 (8), 47.3 (5), 
45.3 (13), 39.7 (4), 39.8, 36.2 (22a, 20b), 35.9 (20a), 35.6 (12), 35.0 (22b), 34.3, 33.8 (25b), 33.2, 
32.9 (15), 31.7 (1), 31.4 (23b), 29.8 (19), 29.0 (2C), 28,2 (7), 27.0 (2), 26.6 (16), 26.0 (10), 25.9 (11), 
25.8 (26a), 25.5 (28), 25.0 (23a), 22.0 (27b), 21.9 (26b), 21.8, 21.0 (6), 20.2 (9), 19.4 (28), 19.2, 18.4 
(21), 18.0 (18), 17.7 (27a), 15.4 (29), 14.2, 13.0; (+)-HRESIMS m/z 907.6204 [M+Na]+ (calcd for 
C60H84NaO5, 2a, 907.6211); m/z 921.6374 [M+Na]
+ (calcd for C61H86NaO5, 2b, 921.6367).  
Compound 3. Prepared according to GP-A using lipoic acid; FC (n-hexane-EtOAc, 9:1); 73% 
yield; thick pale yellow oil; 1H NMR (400 MHz, CDCl3)  7.65 (1H, d, J = 15.7 Hz), 7.18-7.11 (2H, 
m), 7.06 (1H, d, J = 7.8 Hz), 6.42 (0.8H, d, J = 15.9 Hz), 6.40 (1H, d, J = 15.9 Hz), 5.44 (0.2H, d, br, 
J = 4.2 Hz, H-6c,d), 5.13 (0.2H, t, br, J = 6.8 Hz,  H-24a), 4.79 (0.1H, m, H-3d), 4.77-4.72 (1.5H, m, 
H-3a,b,c and H-241b), 4.69 (0.6H, s, br, H-241b), 3.89 (2.4H, s), 3.88 (0.6H, s), 3.63 (1H, quint, br, J 
= 6.8 Hz), 3.22 (1H, ddd, br, J = 10.9, 6.8, 5.5 Hz), 3.15 (1H, dt, J = 10.9 and 6.8 Hz), 2.63 (2H, t, J 
15 
 
= 7.3 Hz), 2.51 (1H, sext, br, J = 6.3 Hz), 2.45-2.41 (0.4H, m), 2.27 (0.6H, sept, J = 6.8 Hz), 1.06 
(1.8H, d, J = 6.8 Hz),  1.05 (1.8H, d, J = 6.8 Hz), 0.71 (0.6H, s), 0.63 (0.8H, d, J = 4.1 Hz, H-19a,b 
endo), 0.40 (0.8H, d, J = 4.1 Hz, H-19a,b exo); 13C NMR (75 MHz, CDCl3)  171.3, 166.6 (1'), 156.9 
(24b), 151.4 (7'), 143.6 (3'), 141.4 (8'), 133.5 (4'), 130.9 (25a), 125.3 (24a), 123.2 (5'), 121.3 (6'), 
119.1 (2'), 111.2 (9'), 106.0 (241b), 80.8 (3), 56.4, 55.9 (10'), 52.2 (17), 48.8 (14), 47.8 (8), 47.2 (5), 
45.3 (13), 40.3 (2C), 39.7 (4), 38.5, 36.3 (22a), 36.1 (20b), 35.9 (20a), 35.5 (12), 35.0 (22b), 34.6, 
33.8 (25b), 32.9 (15), 31.7 (1), 31.3 (23b), 29.8 (19), 28.7, 28,1 (7), 26.9 (2), 26.5 (16), 26.0 (10), 
25.8 (11), 25.8 (26a), 25.5 (28), 25.0 (23a), 24.7, 22.0 (27b), 21.9 (26b), 21.0 (6), 20.2 (9), 19.3 (28), 
18.3 (21), 18.0 (18), 17.7 (27a), 15.4 (29); (+)-HRESIMS m/z 813.4561 [M+Na]+ (calcd for 
C48H70NaO5S2, 3a, 813.4557); m/z 827.4717 [M+Na]
+ (calcd for C49H72NaO5S2, 3b, 827.4713).  
Compound 4. Prepared according to GP-A using 3,4,5-tri[(tert-butyldimethylsilyl)oxy]benzoic 
acid,32 followed by treatment of the crude TBDMS protected intermediate as follows. The crude 
material, dissolved in THF (0.5 mL), was added to a solution of tetrabutylammonium fluoride 
trihydrate (189 mg, 0.6 mmol) in THF (2 mL). The pH was adjusted to 5 by addition of acetic acid 
and the resulting mixture was allowed to stir overnight at room temperature. Then it was diluted with 
EtOAc (20 mL), washed with saturated aq. NH4Cl (3x15 mL), H2O (3x15 mL) and brine (3x15 mL). 
The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure 
to dryness. The resulting crude product was dissolved in acetone and the insoluble solid discarded. 
The acetone was evaporated in vacuo to afford 4; 95% yield; pale brown solid; 1H NMR (400 MHz, 
acetone-d6)  8.68-8.13 (1.3H, m, br), 7.69 (0.8H, d, J = 15.7 Hz), 7.67 (0.2H, d, J = 16.0 Hz), 7.50 
(1H, m), 7.31(1H, dd, J = 7.8, 1.7 Hz), 7.26 (2H, s), 7.21 (1H, d, J = 7.8 Hz), 6.60 (0.8H, d, J = 15.7 
Hz), 6.56 (0.2H, d, J = 16.0 Hz), 5.42 (0.2H, d, br, J = 4.6 Hz, H-6c,d), 5.11 (0.2H, t, br, J = 7.2 Hz, 
H-24a), 4.77-4.66 (2.1H, m), 4.64 (0.1H, m, H-3d), 3.89 (0.6H, s), 3.88 (2.4H, s), 2.96-2.62 (1.7H, 
m, br), 2.42-2.37 (0.4H, m), 2.26 (0.6H, sept, J = 6.9 Hz), 0.73 (0.6H, s), 0.64 (0.8H, d, J = 4.1 Hz, 
H-19a,b endo), 0.45 (0.8H, d, J = 4.1 Hz, H-19a,b exo); 13C NMR (75 MHz, acetone-d6)  166.0, 
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163.9 (1'), 156.5 (24b), 152.1 (7'), 145.4 (2C), 143.7 (3'), 142.2 (8'), 138.7, 133.4 (4'), 130.4 (25a), 
125.2 (24a), 123.6 (5'), 121.4 (6'), 119.8, 118.9 (2'), 111.6 (9'), 109.7 (2C), 106.0 (241b), 80.2 (3), 
55.6 (10'), 52.2 (17), 48.8 (14), 48.1 (8), 47.3 (5), 45.3 (13), 39.5 (4), 36.3 (22a), 36.0 (20b), 35.8 
(20a), 35.5 (12), 35.0 (22b), 33.6 (25b), 32.9 (15), 31.6 (1), 31.2 (23b), 29.5 (19), 29.0 (7), 28.0 (2), 
26.9 (16), 26.0 (10), 25.8 (11), 25.1 (28 and 26a), 24.7 (23a), 21.5 (27b), 21.4 (26b), 20.9 (6), 20.0 
(9), 19.0 (28), 17.9 (21), 17.8 (18), 17.1 (27a), 15.0 (29); (+)-HRESIMS m/z 777.4330 [M+Na]+ 
(calcd for C47H62NaO8, 4a, 777.4337); m/z 791.4488 [M+Na]
+ (calcd for C48H64NaO8, 4b, 791.4493). 
Compound 5. Prepared according to GP-A using (E)-3-(3,4-bis((tert-butyldimethylsilyl)oxy) 
phenyl)acrylic acid,33 followed by treatment of the crude TBDMS protected intermediate, as 
described above for compound 4. The resulting crude product was dissolved in acetone and the 
insoluble solid discarded. The acetone was evaporated in vacuo to afford 5; 98% yield; pale yellow 
solid; 1H NMR (400 MHz, CDCl3)  7.77 (1H, d, J = 16.0 Hz), 7.67 (1H, d, J = 16.0 Hz), 7.22-7.09 
(4H, m), 7.05(1H, d, br, J = 7.5 Hz), 6.90 (1H, d, J = 7.8 Hz), 6.51 (2H, m, br), 6.46 (1H, d, J = 16.0 
Hz), 6.43 (0.8H, d, J = 16.0 Hz), 6.41 (0.2H, d, J = 16.0 Hz), 5.43 (0.2H, d, br, J = 4.2 Hz, H-6c,d), 
5.13 (0.2H, t, br, J = 6.9 Hz, H-24a), 4.84-4.72 (1.6H, m, H-3a,b,c,d and H-241b), 4.70 (0.6H, s, br, 
H-241b), 3.87 (2.4H, s), 3.86 (0.6H, s), 2.49-2.40 (0.4H, m), 2.27 (0.6H, sept, J = 6.7 Hz), 0.72 (0.6H, 
s), 0.63 (0.8H, d, J = 3.9 Hz, H-19a,b endo), 0.40 (0.8H, d, J = 3.9 Hz, H-19a,b exo); 13C NMR (101 
MHz, CDCl3)  167.2, 165.7 (1'), 156.9 (24b), 151.5 (7'), 147.5, 147.2, 144.2, 144.0 (3'), 141.5 (8'), 
133.4 (4'), 130.9 (25a), 127.1, 125.3 (24a), 123.4 (5'), 123.0, 121.4 (6'), 118.9 (2'), 115.5, 114.4, 113.7, 
111.3 (9'), 106.0 (241b), 81.3 (3), 56.0 (10'), 52.3 (17), 48.8 (14), 47.9 (8), 47.3 (5), 45.3 (13), 39.8 
(4), 36.4 (22a), 36.2 (20b), 35.9 (20a), 35.6 (12), 35.0 (22b), 33.8 (25b), 32.9 (15), 31.7 (1), 31.4 
(23b), 29.9 (19), 29.0 (7), 28.2 (2), 27.0 (16), 26.5 (10), 26.0 (11), 25.6 (26a), 25.1 (28), 25.0 (23a), 
22.0 (27b), 21.9 (26b), 21.0 (6), 20.2 (9), 19.4 (28), 18.4 (21), 18.0 (18), 17.7 (27a), 15.4 (29); (+)-
HRESIMS m/z 787.4549 [M+Na]+ (calcd for C49H64NaO7, 5a, 787.4544); m/z 801.4709 [M+Na]
+ 
(calcd for C50H66NaO7, 5b, 801.4701). 
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Hydrolysis of ORY to Phytosterol Mixtures (PS). To a solution of ORY (3.0 g, 5.0 mmol) in 
94% aq. EtOH (32 mL), KOH (2.5 g, 44 mmol) was added and the resulting mixture was stirred under 
reflux. After 8 hrs the reaction was concentrated under reduced pressure and the residue was treated 
with 25 mL of water. The product was extracted into EtOAc (3x30 mL), the extract was dried over 
Na2SO4 and evaporated to give PS (2.1 g, 99% yield); white solid; 
1H NMR (400 MHz, CDCl3)  
5.38 (0.2H, m, H-6c,d), 5.13 (0.2H, t, br, J = 7.1 Hz,  H-24a), 4.74 (0.6H, s, br, H-241b), 4.69 (0.6H, 
s, br, H-241b), 3.55 (0.2H, tt, J = 11.3, 4.8 Hz, H-3c,d), 3.35-3.27 (0.8H, m, H-3a,b), 2.26 (0.6H, sept, 
J = 7.1 Hz), 1.71 (0.6H, s, br), 1.06 (1.8H, d, J = 6.8 Hz), 1.05 (1.8H, d, J = 6.8 Hz), 0.71 (0.6H, s), 
0.58 (0.8H, d, J = 4.1 Hz, H-19a,b endo), 0.36 (0.8H, d, J = 4.1 Hz, H-19a,b exo); 13C NMR (75 MHz, 
CDCl3)  156.9 (24b), 130.9 (25a), 125.3 (24a), 106.8 (241b), 78.8 (3), 52.3 (17), 48.8 (14), 48.0 (8), 
47.1 (5), 45.3 (13), 39.8 (4), 37.3, 35.9 (20a), 36.1 (20b), 35.6 (12), 35.0 (22), 33.8 (25b), 32.9 (15), 
32.0 (1), 31.6 (23b), 31.3 (2), 30.4 (16), 29.9 (19), 28.2 (7), 26.5 (10), 26.0 (11), 25.7 (26a), 25.5 (28), 
25.0 (23a), 22.0 (26b), 21.9 (27b), 21.1 (6), 20.0 (9), 19.3 (28), 18.3 (21), 18.0 (18), 17.6 (27a), 14.0 
(29); (+)-HRESIMS m/z 449.3746 [M+Na]+ (calcd for C30H50NaO, PSa, 449.3754); m/z 463.3902 
[M+Na]+ (calcd for C31H52NaO, PSb, 463.3910). 
Synthesis of PS-C 6-11 
General Procedure B (GP-B) for Esterification of Phytosterols (PS). To a stirred solution of PS 
(0.2 mmol) and the appropriate carboxylic acid (0.24 mmol, or 0.12 mmol in the case of Nα, Nα′-di-
Boc-L-cystine) in anhydrous dichloromethane (2.5 mL), under a nitrogen atmosphere at 0 °C, N,N'-
dimethylaminopyridine (3 mg, 0.024 mmol) and EDC (38 mg, 0.24 mmol) were added. The resulting 
mixture was stirred at room temperature for 8-24 hrs, until the conversion was found to be complete 
by TLC analysis. The resulting solution was diluted with EtOAc (20 mL) and washed with 5% aq. 
H3PO4 (3x10 mL), saturated aq. NaHCO3 (3x10 mL) and brine (3x10 mL). The organic layer was 
dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The 
resulting crude product was purified, if necessary, by flash column chromatography (FC) on silica 
gel, as described below.  
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Compound 6. Prepared according to GP-B using linoleic acid; FC (n-hexane-EtOAc, 19:1); 67% 
yield; colourless wax; 1H NMR (400 MHz, CDCl3)  5.46-5.31 (4.2H, m), 5.13 (0.2H, t, br, J = 7.0 
Hz, H-24a), 4.74 (0.6H, s, br, H-241b), 4.69 (0.6H, s, br, H-241b), 4.67-4.54 (1H, m, H-3), 2.80 (2H, 
t, J = 6.5 Hz), 2.40-2.34 (0.4H, m), 2.33 (2H, t, J = 7.2 Hz),  2.27 (0.6H, sept, J = 6.8 Hz), 1.06 (1.8H, 
d, J = 6.8 Hz), 1.05 (1.8H, d, J = 6.8 Hz), 0.71 (0.6H, s), 0.60 (0.8H, d, J = 4.1 Hz, H-19a,b endo), 
0.37 (0.8H, d, J = 4.1 Hz, H-19a,b exo); 13C NMR (75 MHz, CDCl3)  173.7, 156.9 (24b), 130.9 
(25a), 130.2, 130.1, 128.0, 127.9, 125.3 (24a), 106.0 (241b), 80.4 (3), 52.2 (17), 48.8 (14), 47.9 (8), 
47.2 (5), 45.3 (13), 39.5 (4), 36.3 (22a), 36.1 (20b), 35.9 (20a), 35.5 (12), 34.8 (22b), 34.1, 33.8 (25b), 
32.9 (15), 31.6 (1), 31.5 (23b), 31.3, 29.6 (19), 29.2, 28,1 (7), 27.2 (3C), 26.9 (2), 26.5 (16), 26.0 
(10), 25.8 (11), 25.7 (4C), 25.4 (26a), 25.5 (28), 25.1 (23a), 24.7, 22.6, 22.0 (27b), 21.9 (26b), 20.9 
(6), 20.2 (9), 19.3 (28), 18.3 (21), 18.0 (18), 17.6 (27a), 15.2 (29), 14.1; (+)-HRESIMS m/z 711.6058 
[M+Na]+ (calcd for C48H80NaO2, 6a, 711.6051); m/z 725.6212 [M+Na]
+ (calcd for C49H82NaO2, 6b, 
725.6207). 
Compound 7. Prepared according to GP-B using retinoic acid; FC (n-hexane-EtOAc, 19:1); 87% 
yield; amorphous white solid; 1H NMR (400 MHz, CDCl3)  7.11-6.95 (1H, m), 6.38-6.10 (4H, m), 
5.83 (0.6H, s, br), 5.78 (0.1H, s, br), 5.69 (0.2H, s, br), 5.65 (0.1H, s, br), 5.41 (0.2H, d, br, J = 4.1 
Hz, H-6c,d), 5.13 (0.2H, t, br, J = 7.0 Hz, H-24a), 4.74 (0.6H, s, br, H-241b), 4.72-4.62 (1.6H, m), 
2.39 (3H, s, br), 2.04 (3H, s), 1.75 (3H, s), 1.08-1.03 (12H, m), 0.71 (0.6H, s), 0.61 (0.8H, d, J = 4.1 
Hz, H-19a,b endo), 0.37 (0.8H, d, J = 4.1 Hz, H-19a,b exo); 13C NMR (75 MHz, CDCl3)  163.8, 
156.9 (24b), 156.0, 141.5, 137.4, 137.1, 134.9, 132.1, 130.9 (25a), 130.4, 129.7, 129.1, 125.3 
(24a),116.5, 106.0 (241b), 78.9 (3), 52.3 (17), 48.8 (14), 48.0 (8), 47.1 (5), 45.3 (13), 39.8 (4), 39.6, 
36.3 (22a), 36.1 (20b), 35.9 (20a), 35.5 (12), 35.0 (22b), 34.3, 33.8 (25b), 33.1, 32.9 (15), 32.0 (1), 
31.3 (23b), 30.3 (2C), 29.9 (19), 28,1 (7 and 2), 26.5 (16), 26.0 (10), 25.8 (11), 25.7 (26a), 25.4 (28), 
25.0 (23a), 22.0 (27b), 21.8 (26b), 21.6, 21.1 (6), 20.0 (9), 19.3 (28), 19.2, 18.3 (21), 18.0 (18), 17.6 
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(27a), 15.3 (29), 14.0 (2C); (+)-HRESIMS m/z 731.5731 [M+Na]+ (calcd for C50H76NaO2, 7a, 
731.5738); m/z 745.5890 [M+Na]+ (calcd for C51H78NaO2, 7b, 745.5894). 
Compound 8. Prepared according to GP-B using lipoic acid; FC (n-hexane-EtOAc, 9:1); 94% 
yield; pale yellow foam; 1H NMR (400 MHz, CDCl3)  5.42-5.45 (0.2H, m, H-6c,d), 5.13 (0.2H, t, 
br, J = 7.0 Hz, H-24a), 4.74 (0.6H, s, br, H-241b), 4.69 (0.8H, m, br, H-241b),  4.67-4.56 (1H, m, H-
3), 3.59 (1H, quint, br, J = 6.8 Hz), 3.20 (1H, ddd, br, J = 10.8, 6.8, 5.7 Hz), 3.13 (1H, dt, J = 10.8, 
7.0 Hz), 2.48 (1H, sext, br, J = 6.4 Hz), 2.35 (2H, t, J = 7.4 Hz), 2.26 (0.6H, sept, J = 6.8 Hz), 1.06 
(1.8H, d, J = 6.8 Hz), 1.05 (1.8H, d, J = 6.8 Hz), 0.70 (0.6H, s), 0.60 (0.8H, d, J = 4.1 Hz, H-19a,b 
endo), 0.36 (0.8H, d, J = 4.1 Hz, H-19a,b exo); 13C NMR (101 MHz, CDCl3)  173.3, 156.9 (24b), 
130.9 (25a), 125.3 (24a), 106.0 (241b), 80.6 (3), 56.4, 52.3 (17), 48.8 (14), 47.9 (8), 47.2 (5), 45.3 
(13), 40.2 (2C), 39.8 (4), 38.5, 36.4 (22a), 36.2 (20b), 35.9 (20a), 35.6 (12), 35.0 (22b),  34.7, 33.8 
(25b), 32.9 (15), 32.0 (1), 31.4 (23b), 29.9 (19), 29.8, 28,2 (7), 26.9 (2), 26.5 (16), 26.0 (10), 25.9 
(11), 25.8 (26a), 25.5 (28), 25.0 (23a), 24.9, 22.0 (27b), 21.9 (26b), 21.2 (6), 20.2 (9), 19.4 (28), 18.3 
(21), 18.1 (18), 17.7 (27a), 15.3 (29); (+)-HRESIMS m/z 637.4078 [M+Na]+ (calcd for 
C38H62NaO2S2, 8a, 637.4083); m/z 651.4235 [M+Na]
+ (calcd for C39H64NaO2S2, 8b, 651.4240). 
Compound 9. Prepared according to GP-B using 3,4,5-tri[(tert-butyldimethylsilyl)oxy]benzoic 
acid,32 followed by treatment of the crude TBDMS protected intermediate, as described above for 
compound 4. The resulting crude product was dissolved in acetone and the insoluble solid discarded. 
The acetone was evaporated in vacuo to afford 9; 78% yield; pale yellow foam; 1H NMR (400 MHz, 
CDCl3)  7.35-7.31 (2H, m), 6.10-5.83(3H, m, br), 5.43 (0.2H, m, br, H-6c,d), 5.13 (0.2H, t, br, J = 
6.9 Hz, H-24a), 4.86-4.72 (1.6H, m, H-3 and H-241b), 4.70 (0.6H, s, br, H-241b), 2.49-2.42 (0.4H, 
m), 2.27 (0.6H, sept, J = 6.7 Hz), 0.72 (0.6H, s), 0.64 (0.8H, d, J = 3.9 Hz, H-19a,b endo), 0.41 (0.8H, 
d, J = 3.9 Hz, H-19a,b exo); 13C NMR (75 MHz, acetone-d6)  166.3, 157.3 (24b), 146.0 (2C), 138.5, 
131.3 (25a), 126.0 (24a), 123.2, 109.8 (2C), 106.8 (241b), 81.0 (3), 53.1 (17), 49.6 (14), 49.0 (8), 48.1 
(5), 46.0 (13), 40.6 (4), 37.1 (22a), 36.8 (20b), 36.7 (20a), 36.3 (12), 35.8 (22b), 34.4 (25b), 33.7 (15), 
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32.3 (1), 31.9 (23b), 30.4 (19), 30.1 (7), 29.6 (2), 27.8(16), 27.1 (10), 26.7 (11), 26.6 (28), 25.9 (26a), 
25.5 (23a), 22.3 (27b), 22.2 (26b), 21.6 (6), 20.8 (9), 19.7 (28), 18.7(21), 18.6 (18), 17.9 (27a), 15.9 
(29); (+)-HRESIMS m/z 601.3867 [M+Na]+ (calcd for C37H54NaO5, 9a, 601.3863); m/z 615.4027 
[M+Na]+ (calcd for C38H56NaO5, 9b, 615.4020). 
Compound 10. Prepared according to GP-B using (E)-3-(3,4-bis((tert-
butyldimethylsilyl)oxy)phenyl)acrylic acid,33 followed by treatment of the crude TBDMS protected 
intermediate, as described above for compound 4. The resulting crude product was dissolved in 
acetone and the insoluble solid discarded. The acetone was evaporated in vacuo. The residue was 
purified by FC (n-hexane-EtOAc, 4:1); to afford 10; 94% yield; pale brown powder; 1H NMR (400 
MHz, CDCl3)  7.61 (0.2H, d, J = 15.7 Hz), 7.60 (0.8H, d, J = 16.0 Hz), 7.17-7.11 (1H, m), 7.08-
7.00 (1H, m), 6.94-6.86 (1H, m), 6.35-6.24 (1H, m), 6.04 (1H, m, br), 5.83 (1H, m, br), 5.45-5.36 
(0.2H, m, H-6c,d), 5.13 (0.2H, t, br, J = 6.9 Hz, H-24a), 4.80-4.66 (2.2H, m, H-3 and 2H-241b), 2.46-
2.39 (0.4H, m), 2.27 (0.6H, sept, J = 6.7 Hz), 1.06 (1.8H, d, J = 6.8 Hz), 1.05 (1.8H, d, J = 6.8 Hz), 
0.71 (0.6H, s), 0.63 (0.8H, d, J = 3.9 Hz, H-19a,b endo), 0.39 (0.8H, d, J = 3.9 Hz, H-19a,b exo); 13C 
NMR (75 MHz, CDCl3)  168.1, 156.9 (24b), 146.6, 145.0, 144.0, 130.9 (25a), 127.4, 125.3 (24a), 
122.4, 116.0, 115.5, 114.5, 106.0 (241b), 81.3 (3), 52.3 (17), 48.8 (14), 48.0 (8), 47.2 (5), 45.3 (13), 
39.8 (4), 36.3 (22a), 36.2 (20b), 35.9 (20a), 35.5 (12), 35.0 (22b), 33.8 (25b), 32.9 (15), 31.6 (1), 31.3 
(23b), 29.9 (19), 29.0 (7), 28.1 (2), 26.9 (16), 26.5 (10), 25.9 (11), 25.8 (26a), 25.5 (28), 25.0 (23a), 
22.0 (27b), 21.9 (26b), 21.0 (6), 20.2 (9), 19.4 (28), 18.3 (21), 18.0 (18), 17.6 (27a), 15.3 (29); (+)-
HRESIMS m/z 611.4077 [M+Na]+ (calcd for C39H56NaO4, 10a, 611.4071); m/z 625.4231 [M+Na]
+ 
(calcd for C40H58NaO4, 10b, 625.4227). 
Compound 11. Prepared according to GP-B using Nα, Nα′-di-Boc-L-cystine; FC (n-hexane-EtOAc, 
4:1); 91% yield; amorphous white solid; 1H NMR (400 MHz, CDCl3)   5.63-5.33 (2.4H, m, br, 2NH 
and H-6c,d), 5.13 (0.4H, t, br, J = 6.9 Hz, H-24a), 4.80-4.50 (6.4H, m, H-3 and 2H-241b), 3.38-3.12 
(4H, m), 2.42-2.32 (0.8H, m), 2.27 (1.2, m), 1.48 (18H, s, br), 0.70 (1.2H, s), 0.60 (1.6H, d, J = 3.9 
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Hz, H-19a,b endo), 0.36 (1.6H, d, J = 3.9 Hz, H-19a,b exo); 13C NMR (101 MHz, CDCl3)  170.4 
and 170.0 (1C), 156.8 (24b), 155.1, 130.9 (25a), 125.3 (24a), 106.0 (241b), 82.8 and 82.7 (3), 80.1, 
56.1, 52.3 (17), 48.8 (14), 48.0 (8), 47.2 (5), 45.3 (13), 39.8 (4), 36.4 (22a), 36.1 (20b), 35.9 (20a), 
35.6 (12), 35.0 (22b), 33.8 (25b), 32.9 (15), 31.6 (1), 31.3 (23b), 30.4, 29.9 (19), 29.8 (7), 28.4 (3C), 
28.2 (2), 26.8 (16), 26.5 (10), 26.0 (11), 25.8 (26a), 25.5 (28), 25.0 (23a), 22.0 (27b), 21.9 (26b), 21.2 
(6), 20.2 (9), 19.4 (28), 18.3 (21), 18.0 (18), 17.6 (27a), 15.3 (29); (+)-HRESIMS m/z 1307.9009 
[M+Na]+ (calcd for C78H128N2NaO8S2, 11b, 1307.9004); 
Synthesis of PS-C 12-15 
Synthesis of PS-C 12. To a solution of compound 11 (126 mg, 0.1 mmol) in degassed THF (1.5 
mL), under a nitrogen atmosphere, tri-n-butylphosphine (24 μL, 0.11 mmol) was added at 25 ºC. 
After 2 min of stirring, H2O (9.1 μL, 0.5 mmol) was added and the reaction mixture was stirred for 
24 hrs at the same temperature. The solvent was removed in vacuo and the crude product was purified 
by by FC (n-hexane-EtOAc, 6:1) to afford pure compound 12; 78% yield; colorless foam; 1H NMR 
(400 MHz, CDCl3)  5.52-5.36 (1.2H, m, br, NH and H-6c,d), 5.12 (0.2H, t, br, J = 7.1 Hz, H-24a), 
4.80-4.50 (3.2H, m, SH, H-3 and 2H-241b), 3.11-2.94 (2H, m), 2.42-2.34 (0.4H, m), 2.26 (0.6H, sept, 
J = 6.7 Hz), 1.48 (9H, s, br), 1.06 (1.8H, d, J = 6.8 Hz), 1.05 (1.8H, d, J = 6.8 Hz), 0.71 (0.6H, s), 
0.61 (0.8H, d, J = 4.0 Hz, H-19a,b endo), 0.38 (0.8H, d, J = 4.0 Hz, H-19a,b exo); 13C NMR (75 MHz, 
CDCl3)  170.1 and 169.7 (1C), 156.9 (24b), 155.2, 130.9 (25a), 125.3 (24a), 106.0 (241b), 82.8 (3), 
80.1, 56.0, 52.3 (17), 48.8 (14), 47.8 (8), 47.2 (5), 45.3 (13), 39.7 (4), 36.3 (22a), 36.1 (20b), 35.9 
(20a), 35.5 (12), 35.0 (22b), 33.8 (25b), 32.9 (15), 31.5 (1), 31.3 (23b), 30.3, 29.9 (19), 29.7 (7), 28.3 
(3C), 28.1 (2), 26.9 (16), 26.5 (10), 26.0 (11), 25.8 (26a), 25.6 (28), 24.9 (23a), 22.0 (27b), 21.9 (26b), 
21.1 (6), 20.2 (9), 19.3 (28), 18.3 (21), 18.0 (18), 17.6 (27a), 15.3 (29); (+)-HRESIMS m/z 652.4365 
[M+Na]+ (calcd for C38H63NNaO4S, 12a, 652.4370); m/z 666.4521 [M+Na]
+ (calcd for 
C39H65NNaO4S, 12b, 666.4527). 
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Synthesis of PS-C 13. Phytosterols (500 mg, 1.17 mmol) and succinic anhydride (150 mg, 1.50 
mmol), in dry toluene (2.5 mL), under a nitrogen atmosphere, were combined and stirred at 120 °C, 
until the conversion was found to be complete by TLC analysis. The resulting mixture was diluted 
with toluene, cooled to 4 °C and the solids were filtered off. The filtrate was evaporated on a rotary 
evaporator to give intermediate PS-HS (587 mg, 95% yield); white solid; 1H NMR (400 MHz, CDCl3, 
selected signals)  5.40 (0.2H, d, br, J = 4.1 Hz, H-6c,d), 5.13 (0.2H, t, br, J = 7.1 Hz,  H-24a), 4.74 
(0.6H, s, br, H-241b), 4.69 (0.6H, s, br, H-241b), 4.67 (0.1H, m, H-3d), 4.66-4.60 (0.9H, m), 2.75-
2.60 (4H, m), 2.38-2.32 (0.4H, m), 2.26 (0.6H, sept, J = 7.0 Hz), 1.71 (0.6H, s, br), 1.06 (1.8H, d, J 
= 6.8 Hz), 1.05 (1.8H, d, J = 6.8 Hz), 0.71 (0.6H, s), 0.61 (0.8H, d, J = 4.1 Hz, H-19a,b endo), 0.37 
(0.8H, d, J = 4.1 Hz, H-19a,b exo); 13C NMR (75 MHz, CDCl3)  178.3, 171.8, 156.9 (24b), 130.9 
(25a), 125.3 (24a), 106.0 (241b), 81.3 (3), 52.2 (17), 48.8 (14), 47.9 (8), 47.2 (5), 45.3 (13), 39.5 (4), 
36.3 (22a), 36.1 (20b), 35.9 (20a), 35.5 (12), 35.0 (22b), 33.8 (25b), 32.9 (15), 31.6 (1 and 23b), 29.8 
(19), 29.4, 29.1, 28,1 (7), 26.8 (2), 26.5 (16), 25.8 (11 and 10), 25.7 (26a), 25.4 (28), 25.0 (23a), 22.0 
(27b), 21.9 (26b), 20.9 (6), 20.1 (9), 19.3 (28), 18.3 (21), 18.0 (18), 17.6 (27a), 15.1 (29); (+)-
HRESIMS m/z 549.3919 [M+Na]+ (calcd for C34H54NaO4, PS-HSa, 549.3914); m/z 563.4077 
[M+Na]+ (calcd for C35H56NaO4, PS-HSb, 563.4071). To a stirred solution of the intermediate PS-
HS (106 mg, 0.2 mmol) in anhydrous dichloromethane (2.0 mL) under a nitrogen atmosphere at 0 
°C, trans-resveratrol (0.22 mmol) and DCC (45 mg, 0.22 mmol) were added. The resulting mixture 
was stirred at room temperature for 24 hrs, then it was diluted with Et2O (35 mL) and filtered off to 
remove the precipitate. The filtrate was washed with 5% aq. H3PO4 (3x10 mL), saturated aq. NaHCO3 
(3x10 mL) and brine (3x10 mL). The organic layer was dried over anhydrous Na2SO4, filtered and 
concentrated under reduced pressure to dryness. The resulting crude product was purified by FC (n-
hexane-EtOAc, 1.5:1) to give pure compound 13, as an inseparable 1:1.5 mixture of 13’ and 13” 
isomers; 91% yield; white solid; 1H NMR (400 MHz, CDCl3)  8.07 (0.4H, s), 7.47 (1.2H, d, J = 8.5 
Hz), 7.36 (0.8H, d, J = 8.5 Hz), 7.09 (1.2H, d, J = 8.5 Hz), 7.00 (0.6H, d, J = 16.4 Hz), 6.97 (0.4H, d, 
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J = 16.4 Hz), 6.89 (0.6H, d, J = 16.4 Hz), 6.86-6.77 (2H, m), 6.57 (1.2H, d, br, J = 2.0 Hz), 6.51 
(0.4H, m), 6.31 (0.6H, t, br, J = 2.0 Hz), 6.17-5.46 (1.6H, m, br), 5.40 (0.2H, d, br, J = 4.8 Hz, H-
6c,d), 5.13 (0.2H, t, br, J = 6.8 Hz, H-24a), 4.74 (0.6H, s, br, H-241b), 4.73-4.63 (1.6H, m, H-3 and 
H-241b), 2.96-2.87 (2H, m), 2.82-2.72 (2H, m), 2.39-2.34 (0.4H, m),  2.27 (0.6H, sept, J = 6.7 Hz), 
1.06 (1.8H, d, J = 6.8 Hz), 1.05 (1.8H, d, J = 6.8 Hz), 0.70 (0.6H, s, br), 0.60 (0.8H, m, br, H-19a,b 
endo), 0.37 (0.8H, m, br, H-19a,b exo); 13C NMR (101 MHz, CDCl3)  172.1, 171.2, 157.9, 157.8, 
156.9 (24b), 151.6, 149.9, 140.1, 139.4, 135.2, 130.9 (25a), 129.4, 129.0, 128.9, 127.9, 127.6, 127.4, 
, 125.2 (24a), 121.6, 115.6, 111.0, 110.4, 107.6, 105.9 (241b), 105.4, 102.3, 81.6 (3), 52.2 (17), 48.9 
(14), 47.8 (8), 47.2 (5), 45.3 (13), 39.5 (4), 36.3 (22a), 36.1 (20b), 35.8 (20a), 35.5 (12), 35.0 (22b), 
33.8 (25b), 32.8 (15), 31.5 (1), 31.3 (23b), 29.6 (19), 29.5 (7), 28.1 (2), 26.7 (16), 26.4 (10), 25.8 
(11), 25.6 (26a), 25.4 (28), 24.9 (23a), 21.9 (27b), 21.8 (26b), 20.9 (6), 20.1 (9), 19.2 (28), 18.2 (21), 
17.9 (18), 17.5 (27a), 15.1 (29); (+)-HRESIMS m/z 759.4601 [M+Na]+ (calcd for C48H64NaO6, 13a, 
759.4595); m/z 773.4758 [M+Na]+ (calcd for C49H66NaO6, 13b, 773.4752). 
Synthesis of PS-C 14. To a stirred solution of the intermediate PS-HS (106 mg, 0.2 mmol), prepared 
as above, in anhydrous dichloromethane (2.0 mL) under a nitrogen atmosphere at 0 °C, vanilline (0.22 
mmol) and DCC (45 mg, 0.22 mmol) were added. The resulting mixture was stirred at room 
temperature for 24 hrs, then it was diluted with Et2O (35 mL) and filtered off to remove the precipitate. 
The filtrate was washed with 5% aq. H3PO4 (3x10 mL), saturated aq. NaHCO3 (3x10 mL) and brine 
(3x10 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under 
reduced pressure to dryness. The resulting crude product was purified by FC (n-hexane-EtOAc, 4:1) 
to give pure compound 14; 93% yield; white solid; 1H NMR (400 MHz, CDCl3)  9.98 (0.2H, s), 9.97 
(0.8H, s), 7.53-7.48 (2H, m), 7.26 (0.4H, d, J = 7.8 Hz), 7.25 (0.6H, d, J = 7.8 Hz), 5.40 (0.2H, d, br, 
J = 4.4 Hz, H-6c,d), 5.13 (0.2H, t, br, J = 6.8 Hz, H-24a), 4.74 (0.6H, s, br, H-241b), 4.73-4.58 (1.6H, 
m, H-3 and H-241b), 3.92 (2.4H, s), 3.91 (0.6H, s), 3.02-2.94 (2H, m), 2.82-2.73 (2H, m), 2.38-2.33 
(0.4H, m),  2.26 (0.6H, sept, J = 6.7 Hz), 1.06 (1.8H, d, J = 6.8 Hz), 1.05 (1.8H, d, J = 6.8 Hz), 0.70 
(0.6H, s, br), 0.61 (0.8H, d, J = 4.1 Hz, H-19a,b endo), 0.37 (d, J = 4.1 Hz, H-19a,b exo); 13C NMR 
24 
 
(75 MHz, CDCl3)  191.0, 171.6, 169.9, 156.9 (24b), 152.0, 144.9, 135.4, 130.9 (25a), 125.3 (24a), 
124.7, 123.4,  110.8, 106.0 (241b), 81.3 (3), 56.1, 52.2 (17), 48.8 (14), 47.8 (8), 47.2 (5), 45.3 (13), 
39.5 (4), 36.3 (22a), 36.1 (20b), 35.9 (20a), 35.5 (12), 35.0 (22b), 33.8 (25b), 32.8 (15), 31.6 (1), 31.3 
(23b), 29.5 (19), 29.1 (7), 28.1 (2), 26.8 (16), 26.5 (10), 25.8 (11), 25.7 (26a), 25.4 (28), 25.0 (23a), 
22.0 (27b), 21.9 (26b), 20.9 (6), 20.2 (9), 19.3 (28), 18.3 (21), 18.0 (18), 17.6 (27a), 15.2 (29); (+)-
HRESIMS m/z 683.4289 [M+Na]+ (calcd for C42H60NaO6, 14a, 683.4282); m/z 697.4443 [M+Na]
+ 
(calcd for C43H62NaO6, 14b, 697.4439). 
Synthesis of PS-C 15. To a solution of hispolon methyl ether34 (24 mg, 0.1 mmol), in EtOAc (0.3 
mL), tributylborate (27 μL, 0.1 mmol) was added and the solution was stirred for 30 min at room 
temperature. Then, a solution of 14 (66 mg, 0.1 mmol) and i-propylamine (9 μL, 0.1 mmol) in EtOAc 
(0.4 mL) was added and the reaction mixture was stirred at room temperature for additional 2 hrs. 
After this, 1M aq. HCl (2 mL) was added and the mixture was extracted with EtOAc (3x5 mL). The 
combined organic layers were washed with water until neutral and dried over sodium sulphate. After 
removal of the solvent in vacuo the crude product was purified by FC (n-hexane-EtOAc, 1.5:1) to 
afford 15 (38 mg, 44% yield); yellow solid; 1H NMR (400 MHz, CDCl3)  9.86 (1H, s), 7.56 (2H, d, 
J = 15.7 Hz), 7.11 (2H, dd, J = 8.2, 2.0 Hz), 7.04 (2H, d, J = 2.0 Hz), 6.94 (2H, d, J = 8.2 Hz), 6.35 
(2H, d, J = 15.7 Hz), 5.95 (1H, m, br), 5.65 (1H, s), 5.39 (0.2H, d, br, J = 4.1 Hz, H-6c,d), 5.12 (0.2H, 
t, br, J = 6.8 Hz, H-24a), 4.74 (0.6H, s, br, H-241b), 4.70-4.57 (1.6H, m, H-3 and H-241b), 3.96 (6H, 
s), 2.73-2.63 (2H, m), 2.49-2.42 (2H, m), 2.36-2.31 (0.4H, m), 2.26 (0.6H, sept, J = 6.7 Hz), 1.06 
(1.8H, d, J = 6.8 Hz), 1.05 (1.8H, d, J = 6.8 Hz), 0.70 (0.6H, s, br), 0.60 (0.8H, d, J = 4.1 Hz, H-19a,b 
endo), 0.36 (0.8H, d, J = 4.1 Hz, H-19a,b exo); 13C NMR (101 MHz, CDCl3)  196.9, 178.0, 172.8, 
170.6, 156.9 (24b), 147.9, 146.9, 140.1, 130.9 (25a), 127.6, 125.3 (24a), 122.7, 120.3,  114.9, 109.6, 
106.0 (241b), 100.7, 81.1 (3), 56.0, 52.3 (17), 48.8 (14), 47.9 (8), 47.2 (5), 45.3 (13), 39.5 (4), 36.4 
(22a), 36.1 (20b), 35.9 (20a), 35.6 (12), 35.0 (22b), 33.8 (25b), 32.9 (15), 31.6 (1), 31.5, 31.4 (23b), 
30.2 (19), 29.8 (7), 28.2 (2), 26.8 (16), 26.5 (10), 25.8 (11), 25.7 (26a), 25.4 (28), 25.0 (23a), 22.0 
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(27b), 21.9 (26b), 20.9 (6), 20.2 (9), 19.3 (28), 18.3 (21), 18.0 (18), 17.7 (27a), 15.2 (29); (+)-
HRESIMS m/z 899.5076 [M+Na]+ (calcd for C55H72NaO9, 15a, 899.5069); m/z 913.5228 [M+Na]
+ 
(calcd for C56H74NaO9, 15b, 913.5225). 
Antioxidant Activity 
Antiradical Activity (Scavenging DPPH). Free radical scavenging activity was evaluated by the 
scavenging of DPPH radicals. A methanolic solution of DPPH (40µL, 0.735 mg/mL) was added to a 
solution of the test substance in methanol or ethanol or toluene (800 µL, 0.18 μmol/mL). The 
absorbance was recorded at 545 nm after 30 min of incubation in the dark. Negative control was made 
using the appropriate solvent (e.g. methanol or ethanol or toluene) in absence of the test substance. 
BHA was used as the positive control. The percentage of the DPPH scavenging activity was 
calculated using the equation below: 
% inhibition of DPPH radical = (1- (Asample/Anegative)) x 100, where Asample is the final absorbance of 
the test sample and Anegative is the final absorbance of the negative control. All assays were performed 
in triplicate. 
Fe2+ Chelating Activity (Ferrozine Method). The chelating activity was evaluated by using the 
ferrozine protocol. To an aliquot of the methanolic or ethanolic solution of the test substance (450 
µL, 0.18 μmol/mL) aq. Mohr’s salt (150 µL, 0.125 mM) was added. After 5 min incubation, the 
reaction was initiated by the addition of aq. ferrozine solution (300 µL, 0.5 mM). Absorbance was 
recorded at 545 nm after 10 min incubation at room temperature. A reaction mixture containing 
methanol or ethanol instead of the test substance solution served as the negative control. Quercetin 
was used as the positive control. The percentage of the iron chelating activity was calculated using 
the equation below: 
% Fe2+ chelated = (1- (Asample/Anegative)) x 100, where Asample is the final absorbance of the test sample 
and Anegative is the final absorbance of the negative control. All assays were performed in triplicate. 
β-Carotene Bleaching Inhibition (-Carotene-Linoleic Acid Assay). The antioxidant activity 
was evaluated by using the β-carotene-linoleic acid system. Tween 40 emulsifier (200 mg) and β-
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carotene solution in chloroform (1 mL, 0.2 mg/mL) were mixed. After removing the chloroform in 
vacuo for 10 min at 40 °C, linoleic acid (20 µL) and distilled water saturated with oxygen (30 mL) 
were added to the oily residue. The mixture was vigorously shaken to form a stable emulsion. Aliquots 
of 4 mL of the emulsion were added to the test tubes containing the sample solution in ethanol (1 mL, 
0.18 μmol/mL). The tubes were incubated at 50 °C for 1 h. During that period, the absorbance was 
measured at 450 nm at 15 min intervals, starting immediately after sample preparation (t = 0 min), 
until the end of the experiment (t = 60 min). A reaction mixture containing ethanol instead of the test 
substance solution served as the negative control. BHA was used as the positive control. The 
percentage β-carotene bleaching inhibition was calculated using the equation below: 
% -carotene bleaching inhibition = (1- (msample/mnegative))x100, where msample is the slope of the line 
(deriving from the interpolation of absorbance vs. time) of the test sample and mnegative is the slope of 
the line (deriving from the interpolation of absorbance vs. time) of the negative control. All assays 
were performed in triplicate. 
Antiproliferative Activity. Human breast adenocarcinoma (MDA-MB-468), human cervix 
carcinoma (HeLa) and human medulloblastoma (DAOY) cells were grown in DMEM medium 
(Gibco, Milano, Italy). Both media were supplemented with 115 units/mL of penicillin G (Gibco, 
Milano, Italy), 115 g/mL of streptomycin (Invitrogen, Milano, Italy) and 10% fetal bovine serum 
(Invitrogen, Milano, Italy). These cell lines were purchased from ATCC. Stock solutions (10 mM) of 
the different compounds were obtained by dissolving them in DMSO. Individual wells of a 96-well 
tissue culture microtiter plate were inoculated with 100 L of complete medium containing 8x103 
cells. The plates were incubated at 37 °C in a humidified 5% CO2 incubator for 18 h prior to the 
experiments. After medium removal, 100 L of fresh medium containing the test compound at 
different concentrations was added to each well and incubated at 37 °C for 72 h. The percentage of 
DMSO in the medium never exceeded 0.25%. This was also the maximum DMSO concentration in 
all cell-based assays described below. Cell viability was assayed by the (3-(4,5-dimethylthiazol-2-
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yl)-2,5-diphenyl tetrazolium bromide test as previously described.21 The IC50 was defined as the 
compound concentration required to inhibit cell proliferation by 50%, in comparison with cells treated 
with the maximum amount of DMSO (0.25%) and considered as 100% viability. 
Anticholesterol Activity. The anticholesterol activity was measured as inhibition of the catalytic 
activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCoAR). HMGCoAR, NADPH, 
the assay buffer, the substrate (HMGCoA) and the reference inhibitor (pravastatin) solutions were 
used as provided in the HMGCoAR Assay Kit by Sigma-Aldrich S.r.l. (Milano, Italy). The 
experiments were carried out according to the manufacturer’s instructions at 37 °C. Stock solutions 
of ORY and compounds 1-15 were prepared in DMSO. The final concentration in the assay of the 
tested compounds was 0.05 mg/mL (ORY, 83 µM) or 0.025-0.05 mg/mL (20-87 µM), depending on 
their solubility. The final concentration of DMSO in the assay was 1% (v/v). Specifically, each 
reaction (200 μL) was prepared by adding the reagents in the following order: assay buffer 1 (181 
μL); ORY or compound 1-15 (1 μL); NADPH (4 μL); substrate solution (12 μL) and HMGCoAR 
(catalytic domain; 2 μL). The samples were mixed and the absorbance of NADPH at 340 nm was 
detected by a microplate reader FLUOstar® Omega (BMG Labtech) over 10 min. The HMGCoA-
dependent oxidation of NADPH and the inhibition properties of pravastatin, ORY and compounds 1-
15 were measured by NADPH absorbance reduction which is directly proportional to the enzyme 
activity. 
Each assay was performed in triplicate. Experiments were performed also without the enzyme (blank) 
as well as in the absence of inhibitor/sample (enzyme activity). It was experimentally demonstrated 
that 1% DMSO did not affect the enzyme activity. 
The enzymatic activity (U/mg) was calculated by using the equation below: 
U/mg 
0.55 × 0.6 ×V × 12.44
TV  ) /minA-/minA( blank340   340 

sample
                                             
12.44 = εmM, the extinction coefficient for NADPH at 340 nm is 6.22 mM–1cm–1. 12.44 accounts for 
2 NADPH moles consumed in the reaction. 
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TV = Total volume of the reaction in mL (0.2 mL) 
V = Volume of HMGCoAR used in the assay (mL) 
0.6 = HMGCoAR concentration (mg/mL) 
0.55 = Light path (cm)  
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